Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Operating Margin (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Operating Margin for 8 consecutive years, with 244.88% as the latest value for Q1 2026.

  • For Q1 2026, Operating Margin rose 9189.0% year-over-year to 244.88%; the TTM value through Mar 2026 reached 697.67%, down 22518.0%, while the annual FY2025 figure was 891.07%, 33526.0% down from the prior year.
  • Operating Margin hit 244.88% in Q1 2026 for Kymera Therapeutics, up from 3411.01% in the prior quarter.
  • Across five years, Operating Margin topped out at 40.33% in Q4 2023 and bottomed at 3411.01% in Q4 2025.
  • Average Operating Margin over 5 years is 900.2%, with a median of 469.92% recorded in 2022.
  • On a YoY basis, Operating Margin climbed as much as 22541bps in 2025 and fell as far as -231884bps in 2025.
  • Kymera Therapeutics' Operating Margin stood at 239.36% in 2022, then surged by 83bps to 40.33% in 2023, then crashed by -2608bps to 1092.17% in 2024, then crashed by -212bps to 3411.01% in 2025, then surged by 93bps to 244.88% in 2026.
  • According to Business Quant data, Operating Margin over the past three periods came in at 244.88%, 3411.01%, and 3347.36% for Q1 2026, Q4 2025, and Q3 2025 respectively.